Abstract | BACKGROUND: METHODS: RESULTS:
Sirolimus-related adverse events in the simvastatin plus sirolimus and sirolimus-only groups were 64% and 66% for stomatitis, 50% and 52% for diarrhea, 50% and 45% for peripheral edema, 36% and 61% for acne, 36% and 30% for hypertension, 29% and 27% for proteinuria, 29% and 27% for leukopenia, and 21% and 27% for hypercholesterolemia. The frequency of simvastatin-related adverse events in the simvastatin-only and simvastatin plus sirolimus groups were 60% and 50% for arthralgias and 35% and 36% for myopathy. Before simvastatin plus sirolimus therapy, FEV1 and diffusing capacity of the lung for carbon monoxide (Dlco) yearly rates of change were, respectively, -1.4 ± 0.2 and -1.8 ± 0.2% predicted. After simvastatin plus sirolimus therapy, these rates changed to +1.2 ± 0.5 (P = .635) and +0.3 ± 0.4% predicted (P = .412), respectively. In 44 patients treated with sirolimus alone, FEV1 and Dlco rates of change were -1.7 ± 0.1 and -2.2 ± 0.1% predicted before treatment and +1.7 ± 0.3 and +0.7 ± 0.3% predicted after treatment (P < .001). CONCLUSIONS:
|
Authors | Angelo M Taveira-DaSilva, Amanda M Jones, Patricia A Julien-Williams, Mario Stylianou, Joel Moss |
Journal | Chest
(Chest)
Vol. 147
Issue 1
Pg. 180-187
(Jan 2015)
ISSN: 1931-3543 [Electronic] United States |
PMID | 25167325
(Publication Type: Journal Article, Research Support, N.I.H., Intramural)
|
Chemical References |
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Immunosuppressive Agents
- Simvastatin
- Sirolimus
|
Topics |
- Adult
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Forced Expiratory Volume
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(administration & dosage)
- Immunosuppressive Agents
(administration & dosage)
- Lung Neoplasms
(drug therapy, physiopathology)
- Lymphangioleiomyomatosis
(drug therapy, physiopathology)
- Male
- Middle Aged
- Respiratory Function Tests
- Retrospective Studies
- Simvastatin
(administration & dosage)
- Sirolimus
(administration & dosage)
- Treatment Outcome
- Young Adult
|